I en analyse af cirka 200 prospektivt fulgte graviditeter, hvor der i første trimester blev behandlet med < Zocord > eller anden nært beslægtet HMG- CoA reduktasehæmmer, var incidensen af kongenitte anomalier dog sammenlignelig med incidensen hos befolkningen i almindelighed.
However, in an analysis of approximately 200 prospectively followed pregnancies exposed during the first trimester to< Zocord > or another closely related HMG-CoA reductase inhibi tor, the incidence of congenital anomalies was comparable to that seen in the general population.